New eye drug AVT29 takes on eylea HD in major trial
NCT ID NCT07489131
First seen Mar 25, 2026 · Last updated May 15, 2026 · Updated 8 times
Summary
This study tests a new medicine called AVT29 against an existing drug, Eylea HD, for people with diabetic macular edema (DME), a condition that causes vision loss in people with diabetes. About 256 adults will receive either AVT29 or Eylea HD to see if AVT29 works just as well at improving eyesight over 8 weeks. The goal is to offer a more affordable treatment option for managing DME.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DIABETIC MACULAR EDEMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Site 3004
RECRUITINGBudapest, Hungary
Conditions
Explore the condition pages connected to this study.